Magenta Therapeutics (Magenta Therapeutics) Ending Cash Position : $62.63 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Magenta Therapeutics Ending Cash Position?

Magenta Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2023 was $62.63 Mil.

Magenta Therapeutics's quarterly Ending Cash Position declined from Dec. 2022 ($59.41 Mil) to Mar. 2023 ($50.30 Mil) but then increased from Mar. 2023 ($50.30 Mil) to Jun. 2023 ($62.63 Mil).

Magenta Therapeutics's annual Ending Cash Position increased from Dec. 2020 ($59.93 Mil) to Dec. 2021 ($133.43 Mil) but then declined from Dec. 2021 ($133.43 Mil) to Dec. 2022 ($59.41 Mil).

Magenta Therapeutics Ending Cash Position Historical Data

The historical data trend for Magenta Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Magenta Therapeutics Ending Cash Position Chart

Magenta Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Ending Cash Position

Get a 7-Day Free Trial

60.13

66.85

59.93

133.43

59.41

Magenta Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Ending Cash Position	Get a 7-Day Free Trial															56.61	60.81	59.41	50.30	62.63

Magenta Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Magenta Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	133.43	+	-74.024
	=	59.41

Magenta Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	50.303	+	12.33
	=	62.63

Magenta Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Magenta Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Magenta Therapeutics (Magenta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magenta Therapeutics Inc (NAS:MGTA) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Technology Square, 5th Floor, Cambridge, MA, USA, 02139

Website

https://www.magentatx.com

Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, MGTA-45 and others.

Executives

Peter Evan Harwin	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Tomas Kiselak	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Edward Carr	officer: CHIEF ACCOUNTING OFFICER	1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Ryan Savitz	officer: CHIEF FINANCIAL OFFICER	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Lei Meng	director	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Simrat Randhawa	officer: Chief Medical Officer	7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Avidity Partners Management Lp	director	2828 N HARWOOD STREET, SUITE 1220, DALLAS TX 75201
Marino Garcia	director, officer: CEO and President	C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVENUE, SUITE 2012, NEW YORK NY 10170
Adam M Veness	officer: See Remarks	C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Moulder Leon O Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paula Soteropoulos	director	49 WINONA STREET, PEABODY MA 01960
Jonathan Violin	director	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Third Rock Ventures Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Michael Vasconcelles	director	C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140